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1. ABSTRACT 
 
Background 
The treatment of NSCLC is rapidly changing since new drugs are 
becoming available. Recently, CA has become a standard for the 
first line treatment of NS-NSCLC.  
Previous clinical studies have shown that anti-EGFR MoAb may be 
added to chemotherapy, but the identification of a molecular 
signature can predict their activity and better define their true role. 
Aims 
In absence of data about the MTD of Panitumumab (a MoAb 
targeting the EGFR, potentially active in NS-NSCLC) when 
associated to chemotherapy, we decided to assess the optimal dose 
of panitumumab in combination with CA. Moreover, in view of a 
future phase II study, all pts will be studied for the following 
molecular characteristics: EGFR gene copy number (FISH); EGFR 
IHC; KRAS, BRAF, PI3KCA mutational status; ERCC1 and TS genes 
polymorphisms analysis. A particular attention will be paid to their 
possible correlation with outcome. 
Materials and methods 
Eligible patients must have: histological diagnosis of  previously 
untreated, Stage IIIb or IV, NS-NSCLC, EGFR + (FISH). 
A minimum of 6 to a maximum of 18 patients have to be treated 
with panitumumab at escalating doses (i.e. the first 3 patients at 
5.5 mg/kg q3w, than in absence of dose limiting toxicities (DLT) the 
next 3 patients at 7.2 mg/kg q3w, than in absence of DLT toxicities 
the next 3 patients at 9 mg/kg q3w) in association with CDDP and  
at standard doses.  
Activity and tolerability have been evaluated in terms of response 
rate and NCI-CTC v. 3.0. 
Results 
At the time of writing 8 patients have been screened for EGFR 
overexpression and 4 resulted eligible. None of the 3 patients 
treated with the first dose experienced a DLT, then the fourth 
patient is currently being treated with the second dose (7.2 mg/kg). 
One partial response and two disease stabilization have been 
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obtained, so far. 
Conclusions 
These very  preliminary results have so far showed that 
panitumumab (at the present dose) can be safely associated  with 
CA in NS-NSCLC patients. The study is currently on going. 
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2. INTRODUCTION 
 
Non-small-cell lung cancer (NSCLC) is the leading cause for cancer 
death among men and women in the US[1].  
In Italy, between 2003 and 2005, lung cancer resulted the 3rd most 
frequent tumor among men (13,1% of all tumors), and the 4th 
among women (5% of all tumors), whereas it represents the 
leading cause for cancer-specific death in men (27,6%) and the 3rd 
cause among women (10,3%)[2]. 
The NSCLCs include three main histotypes: squamous cell 
carcinoma, adenocarcinoma and large-cell or undifferentiated 
carcinoma. In Italy, in 2008, it has been estimated that the national 
incidence of each of the considered NSCLC histological subtypes 
was: adenocarcinoma 33.9% in males and 46.1% in females; 
squamous cell carcinoma 28.5% in males and 16% in females; 
large cell carcinoma 2.6% in males and 2.9% in females[3, 4]. 
The treatment strategy is highly dependent upon the stage of the 
disease: surgery represents the gold standard in the early stages, 
multimodality treatments are used for managing locally advanced 
disease, and palliative chemotherapy is the standard of care for 
metastatic disease[5]. In fact, about 40% of patients have 
metastatic disease at the time of diagnosis, so that the efforts of 
the clinicians are directed to ameliorate and innovate the treatment 
options for such population. 
Chemotherapy has become the standard treatment for metastatic 
NSCLC patients since, in 1995, the NSCLC Collaborative Group 
demonstrated that platinum-based chemotherapy provided a 
modest, even though significant, survival benefit and a significant 
improvement of the quality of life (QoL) over the best supportive 
care[6]. A substantial equivalence in terms of efficacy, with 
different tolerability profiles, have been demonstrated between cis- 
and carboplatin, in the CISCA meta-analysis published by Ardizzoni 
et al[7]. In the last few years a significant correlation has been 
found among the expression and the polymorphysms of ERCC1 
gene and the response to platinum compounds[8, 9]. 
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Since the early 90s, various new 3rd generation drugs – i.e. 
vinorelbine, gemcitabine, paclitaxel, docetaxel – demonstrated to be 
active for the treatment of advanced NSCLC patients with no 
significant differences among them in terms of efficacy and minimal 
changes in tolerability[10-14]. 
In the last years, new broadly active agents with refined 
mechanisms of action have become available for NSCLC treatment.  
Alimta (A) is a novel folate-based anticancer compound with a 
broad spectrum of activity against human tumor cell lines, it 
predominantly inhibits thymidylate synthase (TS), but is also active 
against the folate enzymes involved in the de novo synthesis of 
purines and pyrimidines, including dihydrofolate reductase (DHFR) 
and glycinamide ribonucletide formyl transferase (GARFT).  
Several phase II studies have been carried out on A as single-agent 
treatment or as a part of platinum-based as well as platinum free 
combinations, with encouraging results[15-18].  
In 2008, the results of a large, international phase III study 
comparing the association of cisplatin and gemcitabine (CG) versus 
cisplatin and  (CA) for the 1st line treatment of NSCLC have been 
published[19]. Patients received cisplatin 75 mg/m2 on day 1 and 
gemcitabine 1250 mg/m2 on days 1 and 8 (n = 863) or cisplatin 75 
mg/m2 and  500 mg/m2 on day 1 (n = 862) every 3 weeks for up 
to six cycles. The primary outcome was overall survival (OS)  
between treatment arms using a non-inferiority design. With regard 
to the whole patients population, OS for CA was non-inferior to CG 
(mOS, 10.3 vs 10.3 months, respectively; HR = 0.94; 95% CI 0.84 
to 1.05). Interestingly, when performing the pre-planned 
histologically-based subgroup analysis OS was statistically superior 
for CA versus CG in patients with adenocarcinoma (12.6 vs 10.9 
months, respectively, 0.84; 95% CI  0.71 to 0.99; p = 0.03) and 
large-cell carcinoma histology (10.4 v 6.7 months, respectively, 
0.67; CI 95% 0.48 to 0.96; p = 0.03); similarly a nearly 
statistically significant improvement in median PFS was observed 
according to histology (CA median PFS 5.3 months, 95% CI 4.8-
5.7; CG median PFS 4.7 months, 95% CI 4.4-5.4;  CA v CG 
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Adjusted HR 0.90; 95% CI 0.79- 1.02). On the contrary, in patients 
with squamous cell histology, there was an improvement in survival 
with CG vs. CA (10.8 vs 9.4 months, respectively, 1.23; 1.00 to 
1.51; p = 0.05). Regarding the tolerability profile, the rates of 
grade 3 or 4 neutropenia, anemia, and thrombocytopenia (p </= 
0.001); febrile neutropenia (p = 0.002); and alopecia (p < 0.001) 
were lower, and grade 3 or 4 nausea (p = 0.004) higher in the CA 
group. 
On the basis of such experience, A received the regulatory 
authorities approval in combination with cisplatin for the first line 
treatment of NSCLC both in the US and in Europe. 
As already mentioned, A inhibits a number of enzyme systems, 
including DHFR, GARFT, and the bottom one TS, which are of 
paramount importance in tumour cell DNA synthesis: by blocking 
TS, A will finally inhibit tumour cell DNA synthesis[20, 21]. It has 
been found that squamous cell carcinomas have a significantly 
higher level of TS than adenocarcinomas[22]. This could be 
meaningful, because patients with low TS levels in their tumours 
(mainly adenocarcinomas and large cell-carcinoma) are more 
sensitive to the TS blocking effect of A. Evaluating the 
polymorphisms of the promoting region of TS gene, could be helpful 
in defining mRNA expression levels of TS. 
EGFR is a cell surface protein, overexpressed in many cancer types, 
with a role as prognostic and/or predictive factor associated with 
resistance and/or sensitivity to anticancer therapies[23]. The 
autocrine or paracrine stimulation of EGFR by its ligands may have 
a critical role in the progression of tumors expressing this receptor, 
and it has been hypothesized that the inhibition of this pathway 
may inhibit tumor cells survival, proliferation, and metastatic 
process activation. The receptor drives tumor metastasis and 
proliferation by binding the ligands EGF, TGF-α, amphiregulin, 
betacellulin, epiregulin, and/or heparin-binding EGF, which leads to 
dimerization, autophosphorylation and activation of the receptor 
and the subsequent activation of at least three downstream 
intracellular signaling pathways: the Ras-Raf-MAPK pathway, the 
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PI3K-Akt pathway, and the protein kinase C-Jak/Stat pathway[24]. 
There are actually 3 main methods of testing for EGFR[25-27]: the 
first is testing for the gene itself with mutational screening (by 
polymerase chain reaction or by DNA sequencing), and this is the 
most consistent way to identify patients who are extremely likely to 
benefit from EGFR tyrosine kinase inhibitors (TKIs). The next is 
EGFR gene copy number and amplification, which is tested by 
fluorescence in situ hybridization (FISH) and has been investigated 
in several studies. It is not as clearly or consistently predictive as 
mutational screening though still may have some value. The last 
method tests for EGFR protein levels on the cancer cells via 
immunohistochemistry (IHC). 
A key area of debate is the relationship between EGFR mutation, 
increased EGFR gene copy number, EGFR protein expression, and 
outcome after treatment with EGFR inhibitors, i.e. TKIs and 
monoclonal antibodies (mab). Two large, randomized clinical trials 
of EGFR TKI monotherapy in second-/third-line  NSCLC have been 
retrospectively analysed for biomarkers that may predict response 
and survival benefit to EGFR TKIs: BR.21[28-30] and ISEL[25, 31, 
32]. Data from both trials supported EGFR FISH status as a 
potential predictive marker of clinical outcome to TKIs both in terms 
of tumor response and patient survival. Moreover, a recent detailed 
biomarker analysis of a large phase III study highlighted some 
important points. The investigators looked at EGFR gene copy 
number, EGFR mutation status, and EGFR IHC expression and found 
a lot of overlap between IHC, EGFR mutations, and EGFR gene copy 
numbers[33]. Moreover, although EGFR mutation testing is 
available for clinical use, the current 7- to 14-day time frame may 
limit the usefulness of the test, so that EGFR copy number FISH 
evaluation could be used to achieve a faster evaluation[34, 35]. A 
recent report by Dacic et al analyzed the morphological and 
clinicopathological characteristics of 345 surgically treated primary 
lung adenocarcinomas with respect to their EGFR and KRAS 
mutational profile and EGFR FISH status. They found EGFR FISH 
positivity, as defined by the Colorado criteria, as a significant 
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predictor of EGFR mutations, with high polysomy as the strongest 
predictive criterion[36]. To date, however, for anti-EGFR 
monoclonal antibody, no certain data exist on the predictive value 
of EGFR related biomarkers as they only come from retrospective 
analysis[26, 37-39]. 
With regards to anti-EGFR mabs, cetuximab, directed against EGFR 
has been approved in the US on the basis of the results of the FLEX 
study, in which they investigated the value of adding cetuximab to 
the combination of cisplatin and vinorelbine. This study was 
conducted in Europe and enrolled more than 1100 patients who 
were all tested by IHC for EGFR positivity, although it was a very 
lenient definition of EGFR positivity with just a single cell being 
enough to allow patients to be enrolled[37]. The primary endpoint, 
OS, was statistically significantly better in favor of cetuximab with 
chemotherapy, but the median survival difference was only 1.2 
months (11.3 months vs 10.1 months). And because of this, there 
has been a lot of discussion about whether these results are really 
clinically significant, and one of the hopes has been that we might 
find a subgroup of patients who are far more likely to benefit 
meaningfully from cetuximab. Recently, there was a presentation of 
results as a function of whether patients had high EGFR expression 
or low EGFR expression, the definition being a product of the 
intensity of staining and the proportion of cancer cells that are 
positive[38]. Approximately one third of the patients had high EGFR 
expression. Looking at the median OS for high EGFR expression and 
low EGFR expression and comparing them for chemotherapy plus 
cetuximab vs chemotherapy alone, it was 9.8 for chemotherapy 
plus cetuximab and 10.3 for chemotherapy alone, whereas in the 
high EGFR expression it was 12 months for chemotherapy plus 
cetuximab and 9.6 months for chemotherapy alone. This suggests 
that there could be a meaningful way to select patients far more 
likely to benefit in the range of 2 or more months and not pursue 
this for other patients. 
Panitumumab is a high affinity human IgG2 monoclonal antibody 
directed against human EGFR[40]. Panitumumab blocks EGFR 
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binding of the ligands EGF, TGF, amphiregulin, betaregulin, 
epiregulin, and heparin-binding EGF. 
In vitro studies demonstrated that treatment with panitumumab 
inhibited ligand-induced EGFR autophosphorylation and EGFR 
dependent cellular response, including extracellular acidification, cell 
proliferation, and production of angiogenic factors by tumor cells. 
Panitumumab alone demonstrated to be able to eradicate 
established xenograft A431 epidermoid carcinoma tumors and 
inhibit tumor growth of breast, renal, pancreatic, head and neck, 
prostate, ovarian, and NSCLC. Combination of panitumumab and 
chemotherapeutic agents resulted in greater inhibition of tumor 
growth in colon, lung, breast, ovarian, pancreas, and head and neck 
xenograft tumors than either agent alone. Panitumumab with 
radiotherapy also resulted in increased inhibition of head and neck 
and lung cancer tumor xenografts. These results indicate that 
panitumumab may play a therapeutic role in the treatment of 
multiple EGFR expressing human solid tumors[40-42]. 
To date, panitumumab has been evaluated in combination with 
chemotherapy in subjects with CRC, NSCLC, and SCCHN. 
Data from multiple clinical trials of panitumumab in CRC have 
demonstrated that patients whose tumors contain activating 
mutations in the KRAS gene do not derive  clinical benefit from 
antibody therapy and have significantly shortened survival 
compared to patients whose tumor expresses wild-type KRAS[43, 
44], whereas no certain data are available with regard to NSCLC 
patients. 
No clear additive effects were observed in the NSCLC setting when 
panitumumab was combined with carboplatin/paclitaxel. The 
preliminary and updated results of this phase II randomized study 
have not shown significant differences in response rate, time to 
progression and overall survival favouring panitumumab receiving 
patients[41]. One concern about this trial is that patient population 
was unselected. Identification of a molecular signature predicting 
benefit from anti-EGFR antibodies might be helpful in defining their 
true role in the treatment of such patients.  
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In absence of data about the Maximum Tolerable Dose of 
panitumumab when associated to chemotherapy, we decided to 
assess the optimal dose of panitumumab in combination with the 
combination cisplatin-alimta (CA). Moreover, in view of a future 
phase II study, all pts will be studied for the following molecular 
characteristics: EGFR gene copy number (FISH); EGFR IHC; KRAS, 
BRAF, PI3KCA mutational status; ERCC1 and TS genes 
polymorphisms analysis. A particular attention will be paid to their 
possible correlation with outcome. 
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3. AIMS OF THE THESIS 
 
Primary Objective: to assess the MTD dose of panitumumab in 
combination with CA.  
 
Secondary objectives:  
• Overall Response Rate (ORR), calculated as the sum of 
complete and partial tumour responses observed, divided by the 
number of evaluable patients. 
• Tolerability, evaluated on the total number of patients 
receiving at least one cycle of treatment according to NCI-CTC v3.0. 
• The following molecular characteristics - EGFR gene copy 
number (FISH); EGFR IHC; KRAS, BRAF, PI3KCA mutational status; 
ERCC1 and TS genes polymorphisms analysis – will be collected.
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4. MATERIALS AND METHODS 
 
4.1 INCLUSION CRITERIA 
• Histological diagnosis of  previously untreated, non-
squamous, NSCLC, EGFR FISH + 
• Stage IIIb or IV 
• Age 18-75; (for elderly pts, > 70 aa, “Comprehensive 
Geriatric Assessment” must be performed) 
• PS ECOG 0-1 
• At least 1 measurable lesion (RECIST) 
• Haematology:  
o Neutrophil count ≥1.5x109/L 
o Platelet count ≥100x109/L 
o Leucocyte count > 3,000/mm  
o Hemoglobin ≥ 9 g/dL 
• Hepatic Function: 
o Total bilirubin ≤ 1.5 time the upper normal limit (UNL) 
o ASAT ≤ 2.5xUNL in absence of liver metastases, or ≤5xUNL 
in presence of liver metastases 
o ALAT ≤ 2.5xUNL in absence of liver metastases, or ≤5xUNL 
in presence of liver metastases 
• Renal Function: serum creatinine ≤1.5xUNL  
• Metabolic Function 
                   o Magnesium ≥ lower limit of normal. 
                   o Calcium ≥ lower limit of normal. 
 
• Written informed consent. 
• Geographical accessibility to the participating center and 
compliance with  treatment and scheduled follow-up. 
 
4.2 EXCLUSION CRITERIA 
• Previous (within 5 years of study entry) or concurrent  
neoplasm other than adequately managed in situ  carcinoma of the 
cervix  and/or  basal cell skin cancer 
• Clinically detectable brain metastases 
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• Concurrent treatment with other chemotherapeutic, 
hormonal or biologic antineoplastic agents. 
• Prior exposure to cisplatin in the adjuvant setting 
• Previous chemotherapy for metastatic disease 
• Previous radiotherapy 
• Clinically significant cardiovascular disease (including 
myocardial infarction, unstable angina, symptomatic congestive 
heart failure, serious uncontrolle
before enrollment/randomization  
• History of interstitial lung disease e.g. pneumonitis or 
pulmonary fibrosis or evidence  of interstitial lung disease on 
baseline chest CT scan. 
• Subject pregnant or breast feeding, or planning to become 
pregnant within 6 months after the end of treatment. 
• Subject (male or female) is not willing to use highly effective 
methods of  contraception (per institutional standard) during 
treatment and for 6 months (male  or female) after the end of 
treatment. 
 
4.3 PRETREATMENT EVALUATION 
Before enrolment the following procedures must be carried out and 
the samples collected: 
 
- Complete history and physical examination, ECOG PS; 
- EKG, echocardiography, blood pressure; 
- blood cell count (BCC) and serum chemistry tests; 
- CEA, Ca 19.9, NSE, Cyfra 21.1 (optional); 
- chest X rays; 
- bone scan; 
- CT scan of the brain, chest and abdomen; 
- a 10 cc EDTA blood sample stored at 20°C. Subsequently sent in 
dry ice to the centralized lab; 
- five 8-10 micron tumor slices in Eppendorf tubes, (DNA 
extraction and mutational analysis) and three slides (section of 2-3 
micron) for the FISH analysis. 
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- Other exams will be performed as needed. 
 
4.4 STUDY DESIGN 
The treatment schedule include: 
- CDDP 75 mg/m2 d1 q21 (min 2 - max 6 cycles) 
- Alimta 500 mg/m2 d1 q21 (min 2 - max 6 cycles), with standard 
pre-medication. 
As regards panitumumab dose, it is administered to successive 
patient cohorts in a dose-escalating fashion to identify the MTD 
using a traditional three or six patient-per-cohort design. The 
starting and maximum doses have been calculated based on on 
previous phase I/II studies of panitumumab. 
The dose-finding study should be performed in a minimum of 6 to a 
maximum of 18 patients (i.e. the first 3 patients at 5.5 mg/kg q3w, 
than in absence of dose limiting toxicities (DLT) the next 3 patients 
at 7.2 mg/kg q3w, than in absence of DLT the next 3 patients at 9 
mg/kg q3w; in any case, the phase I study will be stopped after the 
first cohort treated at 9 mg/kg) (fig.1). The minimum lenght of 
observation will be at least of two cycles. 
 
 
 
Figure 1. Study flow chart 
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Toxicity evaluation 
Toxicities is recorded and graded at each administration according 
to the NCI CTC vs 3 criteria. Non-hematologic toxicity of each cycle 
is assessed before the start of the next cycle. The worst toxicity 
encountered during the whole treatment is reported for each 
patient. 
It is important to be noted that, when escalating Panitumumab dose 
only DLT specific for Panitumumab, i.e. G4 Gastrointestinal 
disorders (diarrhea, nausea, vomiting); G3/4 general disorders 
(fatigue, infusion reactions, pyrexia and chills, mucosal 
inflammation); G4 metabolism and nutrition disorders 
(hypomagnesemia, hypocalcemia, hypokalemia, dehydration); G3/4 
nervous system disorders (headhache), G3/4 respiratory disorders 
(cough, dyspnea); G4 skin and eye disorders (dermatitis acneiform, 
pruritus, erythema, rash, skin exfoliation, dry skin, skin fissures, 
paronychia, irsutism, hypertricosis, conjunctivitis, growth of 
eyelashes, increased lacrimation, dry eye, ocular hyperemia, nasal 
dryness, nasal bleeding, stomatitis, dry mouth, chapped lips) G3/4 
vasculars disorders (pulmonary embolism) are considered as DLT. 
Nevertheless, if G3-4 toxicities not commonly considered as 
attributable to the chemotherapeutic agents (cisplatin, alimta) are 
observed, these should be considered as related to panitumumab 
and then as DLTs.  
The panitumumab total dose is calculated based on the subject’s 
actual body weight at baseline and could not be re-calculated unless 
the actual body weight changes by at least 10%.  
Panitumumab should be continued until progressive 
disease/unacceptable toxicity/patient’s refusal/death occur. 
 
Clinical assessment 
After the administration of 2 cycles, patients will undergo restaging 
of the disease: 
- If progression of disease occurs, the treatment will stopped 
and the patient will be followed up for survival; investigators will be 
free of giving any further antitumor treatment according to each 
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partecipating centre practice. 
- in case of a complete response (CR), partial response (PR) or 
stable disease (SD), patients will receive  further 2 cycles of 
chemotherapy; a maximum of 6 cycles is planned; panitumumab 
will be continued until progressive disease/unacceptable 
toxicity/patient’s refusal/death occur. 
 
Statistical analysis 
This is  a phase I safety and tolerability trial conducted to determine 
the MTD of panitumumab in association with cisplatin and alimta. 
The sample size was based on the standard phase I design of 
toxicity assessment. In addition, tumor response and biological 
features are evaluated as secondary objectives as the proportion of 
patients experiencing radiologically confirmed response and the 
proportion of patients with every molecular feature, respectively. 
For the safety analysis, incidence rates of grade 3/4 adverse events 
(DLT), drug-related adverse events, and hematologic/biochemical 
toxicities are reported based on National Cancer Institute Common 
Toxicity Criteria version 3 by dose level. 
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5. RESULTS 
 
Since September 2011 8 patients have been screened for enrolment 
and 4 have been excluded because of the absence of EGFR FISH 
amplification. All of the 4 patients included until now have been 
treated with at least one dose of the drug, and can be included in 
the safety analysis, whereas only 3 patients are evaluable for 
response to date. Patient characteristics at baseline are summarized 
in Table 1. 
 
         Table 1. Patient baseline characteristics 
Characteristic n 
 
Total patients  4 
Sex 
   Male  
   Female  
 
3 
1 
Age 
   Median 
   Range 
 
60 y 
53-66 
ECOG PS 
   0 
   1 
 
3 
1 
Tumor Histology 
   Adenocarcinoma 
   Large cell carcinooma 
 
3 
1 
 
EGFR FISH + 
N° of metastatic sites 
   1 - 2 
   >2 
4 
 
3 
1 
ECOG, Eastern Cooperative Oncology Group; PS, 
performance status. 
 
The first 3 patients have been treated at the first dose level (i.e. 5.5 
mg/kg, with no observation of the G3/4 panitumumab-related 
adverse events described above (DLT), so that the fourth patient is 
currently been treated at the next dose level (i.e. 7.2 mg/kg). 
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Table 2. Summary of the results per patient 
Patient 1 
   Sex  
   Age 
   PS  
   Dose level 
   N° of cy 
   Best response 
   DLT 
 
 
Male 
66 
1 
5.5 mg/kg 
2 
SD 
No 
Patient 2 
   Sex  
   Age 
   PS  
   Dose level 
   N° of cy 
   Best response 
   DLT 
 
 
Male 
63 
0 
5.5 mg/kg 
6 cy + 4 M 
PR 
No 
Patient 3 
   Sex  
   Age 
   PS  
   Dose level 
   N° of cy 
   Best response 
   DLT 
 
 
Male 
57 
0 
5.5 mg/kg 
6 cy 
SD 
no 
Patient 4 
   Sex  
   Age 
   PS  
   Dose level 
   N° of cy 
   Best response 
   DLT 
 
Female 
53 
0 
7.2 mg/kg 
1 cy 
NE 
No 
PS, performance status; N°, number; cy, cycle; SD, stable 
disease; DLT, dose limiting toxicity; M, maintenance; PR, partial 
response; NE, not evaluated. 
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As regards tumor response, patient number 1 achieved stable 
disease (SD) after 2 cycles but experienced clinical progression of 
the disease after the third cycle that lead to treatment 
discontinuation; patient number 2 achieved a partial response after 
2 cycles and subsequent SD lasting more than 6 months, and is 
currently being treated with panitumumab maintenance; patient 
number 3 achieved SD after two cycles, that was confirmed after 4 
cycles, but progressive disease recently occurred after the 6th cycle 
administration. 
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6. DISCUSSION 
 
NSCLC is among the leading causes of cancer death in the Western 
countries. The treatment of NSCLC is rapidly changing since new 
drugs are becoming available and quite recently, the doublet 
cisplatin-alimta has become a standard for the first line treatment 
of NS-NSCLC.  
EGFR is a cell surface protein, with a significant role as a prognostic 
and/or predictive factor, deeply involved in the progression of 
tumors expressing this receptor. It has been proved that the 
inhibition of this pathway may inhibit tumor cells survival and 
proliferation, in certain patient population. There are two main 
classes of EGFR inhibitor that have been experimented in the 
treatment of NSCLC: TKIs and mab. 
A key area of debate is the relationship between EGFR mutation, 
increased EGFR gene copy number, EGFR protein expression, and 
outcome after treatment with EGFR inhibitors. EGFR protein 
expression assessed by IHC, EGFR gene copy number assessed by 
FISH, and mutations in the EGFR or other downstream genes, have 
been under investigation as potential biomarkers that may predict 
sensitivity to anti-EGFR therapy [25, 28-32]. Data from these trials 
supported EGFR FISH status as a potential predictive marker of 
clinical outcome of patients treated with anti-EGFR agents. To date, 
however, for anti-EGFR monoclonal antibody, no certain data exist 
on the predictive value of EGFR related biomarkers as they only 
come from retrospective analysis [26, 37-39]. 
Panitumumab is a high affinity human IgG2 monoclonal antibody 
directed against human EGFR [40].  
Previous studies demonstrated that panitumumab alone or in 
combination with chemotherapeutic or targeted agents or radiation 
may play a therapeutic role in the treatment of multiple EGFR 
expressing human solid tumors [40-42]. 
To date, panitumumab has been evaluated in combination with 
chemotherapy in subjects with CRC, NSCLC, and SCCHN. In the 
NSCLC setting when panitumumab was combined with 
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carboplatin/paclitaxel no beneficial effect has been observed, with 
no significant differences in activity and/or efficacy vs 
carboplatin/paclitaxel alone [41]. One concern about this trial is 
that patient population was unselected, as that of the FLEX trial 
[37, 38].  
Therefore, our study is aimed to assess the optimal dose of 
panitumumab to be combined with cisplatin and alimta  for the 
treatment of patients affected by advanced non-squamous NSCLC 
(EGFR FISH+). Morever, the identification of a molecular signature 
predicting benefit from anti-EGFR antibodies might be helpful in 
defining their true role in the treatment of such patients.  
Our very preliminary results demonstrated panitumumab in 
combination with CA to be safe in such population of patients at the 
first dose (5.5 mg/kg),  with no DLT observed to date and one 
patient currently being treated at the higher dose (7.2 mg/kg).  
Due to the very small small sample enrolled to date, no definitive 
conclusion can be drawn, but the results in terms of response are 
encouraging as those of tolerability. 
Very interesting data are expected to be collected with regard to 
moleculare characteristic of these subjects and the possible 
correlation with various outcome measures. 
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7. CONCLUSIONS 
 
These are very  preliminary results. Panitumumab 5.5 MG/KG can 
be safely associated  with CA in NS-NSCLC EGFR FISH + patients, 
achieving a good disease control rate. No definitive conclusion can 
be drawn since the study is currently on going.  
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CARCINOSI PERITONEALE DA NEOPLASIA A SEDE PRIMITIVA SCONOSCIUTA CON 
DIFFERENZIAZIONE NEUROENDOCRINA: SOPRAVVIVENZA A LUNGO TERMINE E 
RUOLO DEGLI ANALOGHI  DELLA SOMATOSTATINA 
Laura Palmeri, Sergio Rizzo 
Dipartimento di Discipline Chirurgiche ed Oncologiche, Università degli Studi di Palermo - Via del 
Vespro, 129 - 90127 Palermo- - E-mail: laura.palmeri@gmail.com 
 
IL PAZIENTE 
Paziente di sesso maschile, 63 anni all’epoca della prima diagnosi (giugno 2005). 
In anamnesi cirrosi epatica HBV correlata, nota dal 2004 (score di Child-Pugh A). Tra la fine del 2004 e i 
primi mesi del 2005 si ricoverava ripetutamente c/o altro presidio ospedaliero in reparto di nefrologia, per 
sindrome nefrosica in stadio III, correlata all’infezione da HBV. Nel mese di febbraio ricorreva 
all’ospedalizzazione, in reparto di nefrologia, per stato anasarcatico, risoltosi con opportuna terapia 
diuretica. Durante i successivi controlli, a causa del permanere di ascite refrattaria, eseguiva TC torace-
addome ± mdc che metteva in evidenza la presenza di carcinosi peritoneale, in assenza di una primitività 
chiaramente evidenziabile. 
Giungeva alla nostra osservazione nel giugno 2005, inviato, per competenza, dallo specialista nefrologo. 
 
L’ESAME OBIETTIVO 
All’atto del ricovero il paziente si mostrava in discrete condizioni cliniche generali, PS ECOG 1.  
L’obiettività dei principali organi ed apparati, inclusa l’EDAR, risultava negativa, fatta eccezione per la 
presenza di versamento ascitico di lieve entità; non si repertava nessuna linfoadenomegalia degna di nota 
nelle sedi clinicamente esplorabili. 
 
GLI ESAMI DI LABORATORIO E LE INDAGINI STRUMENTALI 
Gli esami ematochimici risultavano nella norma, fatta eccezione per una lieve alterazione degli indici di 
funzionalità renale e anemia; la ricerca del sangue occulto nelle feci era anch’essa negativa. 
Eseguiva una TC torace-addome a strati sottili (12/06/2005) che evidenziava la presenza di fegato cirrotico, 
splenomegalia, circoli collaterali perisplenici, perigastrici e mesenterici; varici esofagee; versamento 
ascitico sovra e sotto-mesocolico; alcune millimetriche formazioni tondeggianti, iperdense nel contesto del 
ventaglio mesenterico come da carcinosi peritoneale. Negativi i reperti mediastinici e toracici. 
I marcatori tumorali risultavano in parte alterati: CEA 5.23 ng/mL (<5), Ca125 1217,4 U/mL, (<35), CgA 
>1220 ng/mL (9-98), Ca19.9, NSE, alfaFP e PSA nella norma. 
Veniva pertanto inviato ad un reparto di chirurgia e sottoposto a laparoscopia diagnostica, con biopsia 
epatica e dei noduli peritoneali, drenaggio del liquido ascitico. 
L’esame istologico dimostrava la presenza di cirrosi epatica; carcinosi peritoneale Cromogranina A +, 
Sinaptofisina +, NSE -, S100 -. 
Nell’impossibilità di eseguire l’Octreoscan, il paziente eseguiva PET total-body con FDG (17/07/2005) 
(Figura 1) che rilevava la presenza di diffuso, relativo iperaccumulo del tracciante di pertinenza peritoneale, 
disposto a grembiule in corrispondenza della parete anteriore dell’addome.  
 
LE CONCLUSIONI DIAGNOSTICHE 
Veniva diagnosticata carcinosi peritoneale da neoplasia ad origine primitiva sconosciuta con componente 
neuroendocrina. 
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Figura 1. Tomoscintigrafia globale corporea del 11/7/2005 
LA TERAPIA E IL DECORSO CLINICO 
Nel mese di Luglio 2005 iniziava pertanto chemioterapia con Carboplatino AUC 4 g1, Paclitaxel 70 mg/m2 
g1,8 ogni 21 giorni per 3 cicli, e trattamento con Lanreotide 30 mg 1 fl i.m. ogni 28 giorni. Le tossicità 
riscontrate, un episodio di neutropenia febbrile e due di diarrea refrattaria, determinavano il prolungamento 
dell’intervallo interciclo. La rivalutazione della malattia mediante TC torace-addome (03/01/2006) e PET 
(03/02/2006) (Figura 2) mostravano parziale regressione della patologia peritoneale. Si osservavano inoltre 
normalizzazione del CEA 4.79 ng/mL (<5) e significativa riduzione della CgA 214 ng/mL (9-98). 
 
Figura 2. Tomoscintigrafia globale corporea del 3/2/2006 
 
Nonostante la buona risposta ottenuta, considerate le tossicità riscontrate, si sospendeva la chemioterapia e 
proseguiva Lanreotide. Le successive rivalutazioni dimostravano una stabilizzazione della malattia fino a 
novembre 2006, quando sia la TC torace-addome (29/11/2006) che la PET (15/12/2006) (Figura 3) 
identificavano la presenza di progressione polmonare. A Gennaio 2007 il paziente riprendeva il trattamento 
chemioterapico secondo lo schema precedente (con riduzione del Paclitaxel a 60 mg/m2) che sospendeva 
dopo 4 cicli (Maggio 2007) per trombocitopenia persistente G3-4. La rivalutazione confermava la presenza 
della malattia a livello peritoneale ma non evidenziava più la localizzazione polmonare. Si osservava inoltre 
normalizzazione della CgA. Ha proseguito fino ad oggi terapia con Lanreotide. 
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Figura 3. Tomoscintigrafia globale corporea del 15/12/2006 
LA DISCUSSIONE 
Le successive rivalutazioni di malattia, da Settembre 2007 ad oggi, hanno mostrato una risposta completa: 
negativizzazione reperti TC e PET (Figura 4) e normali livelli di CgA (ultimo dosaggio Aprile 2008 2.9 
ng/mL, v.n. 0-100). Il paziente è in condizioni cliniche generali buone (ECOG-PS 0) prosegue i controlli 
previsti. 
Il sito di origine di un carcinoma istologicamente determinato non viene identificato in circa il 3% dei 
pazienti [45]: questi tumori vengono generalmente chiamati a primitività ignota. Essi rappresentano un 
gruppo autonomo ed eterogeneo, che si presenta alla prima diagnosi con una o più lesioni secondarie, la cui 
origine non può essere individuata dopo anamnesi approfondita, esame obiettivo e opportune procedure di 
diagnostica [46]. Gli istotipi più frequenti sono l’adenocarcinoma e il carcinoma indifferenziato, seguono 
poi altri tipi istologici quali squamo-cellulari, tumori neuroendocrini, melanomi e sarcomi. 
 
Figura 4. Tomoscintigrafia globale corporea del 13/09/2007 
La sopravvivenza di questi pazienti supera raramente i 12 mesi e meno del 10% di loro è vivo a 5 anni [47]. 
La maggior parte di questi tumori è refrattaria ai trattamenti sistemici, cosicchè l’individuazione di gruppi a 
migliore prognosi, che possano beneficiare di specifici trattamenti è di fondamentale importanza. 
Attualmente non  esiste uno standard di trattamento, anche se schemi a base di Cisplatino hanno portato 
buoni tassi di risposta [48]. Negli ultimi anni i nuovi farmaci sono stati ampiamente indagati ed hanno 
fornito risultati incoraggianti [49, 50] 
Nel nostro caso, è stato scelto uno schema a base di platino, con il Carboplatino preferito al Cisplatino per 
via dell’alterata funzionalità renale del paziente, in associazione a Paclitaxel.  
L’istotipo neuroendocrino, unitamente agli elevati livelli di CgA, hanno suggerito l’associazione di un 
analogo della somatostatina. Il risultato ottenuto, sia in termini di risposta, che di sopravvivenza ha superato 
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ogni aspettativa e può aggiungere nuove motivazioni per la ricerca di trattamenti il più possibile specifici ed 
individualizzati per questo tipo di pazienti.  
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